Poseida is a clinical-stage biopharmaceutical company building out a wholly-owned pipeline of Chimeric antigen receptor T cell (CAR-T) product candidates, initially focused on the treatment of haematologoical malignancies, like multiple myeloma, and solid tumours, like prostate cancer.

Viamet represents a financial interest for Malin in VIVJOA™, an FDA-approved medication for the treatment of recurrent vulvovaginal candidiasis (RVVC), an unmet need in women’s health, and in a Phase 3 compound for the treatment of onychomycosis, fungal nail infection.

Xenex is a commercial-stage medical device company focused on reducing healthcare-associated infections with its unique non-mercury, full-spectrum disinfection LightStrike^TM Germ-Zapping^TM robots. Xenex aims to become the new standard of care for disinfection in healthcare facilities worldwide, eliminating harmful bacteria, viruses and fungi which can cause healthcare associated infections in patients and staff.

WaveBreak Therapeutics (formerly Wren Therapeutics) is a privately-held company focussed on the development of breakthrough medicines for the treatment of protein misfolding diseases including Alzheimer's and Parkinson's. WaveBreak’s proprietary approach is based on more than a decade of research focused on the chemical kinetics of the protein misfolding process. WaveBreak is developing a broad pipeline of small molecule and antibody therapeutics, as well as diagnostics, spanning neurology, ophthalmology and metabolic diseases.

KNOW Bio is a privately held life science company utilising its extensive catalogue of intellectual property in the fields of nitric oxide and precision light therapy to develop unique treatments to revolutionise the standard of care for many indications.

Artizan is an early-stage biotechnology company focused on developing a platform to eliminate disease-causing bacteria in the gut microbiota. Artizan's initial focus is on inflammatory bowel disease, specifically Crohn's Disease and Ulcerative Colitis.